Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Second Sight Medical Products, Inc.

Argus retinal prosthesis, also known as a bionic eye, is an electronic retinal implant manufactured by the American company Second Sight Medical Products. It is used as a visual prosthesis to improve the vision of people with severe cases of retinitis pigmentosa. The Argus II version of the system was approved for marketing in the European Union in March 2011, and it received approval in the US in February 2013 under a humanitarian device exemption. The Argus II system costs about US$150,000, excluding the cost of the implantation surgery and training to learn to use the device.

Investment goal date:
Dividends reinvested
Second Sight Medical Products, Inc. EYES report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q2 2017
2017-08-01
0.0000
-0.1200
Q1 2017
2017-05-03
0.0000
-0.1600
Q4 2016
2017-03-09
0.0000
-0.2400
Q3 2016
2016-11-02
0.0000
-0.2000
Q2 2016
2016-07-28
0.0000
-0.2300
Q1 2016
2016-04-28
0.0000
-0.1600
Q4 2015
2016-03-03
0.0000
-0.1500
Q3 2015
2015-10-29
0.0000
-0.1300
Q2 2015
2015-08-04
0.0000
-0.1400
Q1 2015
2015-05-13
0.0000
-0.1400
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BlackRock Fund Advisors
475860
BlackRock Inc.
898337
BlackRock Institutional Trust Company, N.A.
375166
BNP PARIBAS ARBITRAGE, SA
696273
CARL DOMINO INC
112719
Frigate Ventures LP
229077
GEODE CAPITAL MANAGEMENT, LLC
142231
KCG Holdings, Inc.
69592
NORTHERN TRUST CORP
156278
ORACLE INVESTMENT MANAGEMENT INC
50804
Psagot Investment House Ltd.
195999
SCHWAB CHARLES INVESTMENT MANAGEMENT INC
140771
STATE STREET CORP
223757
TIAA CREF INVESTMENT MANAGEMENT LLC
50867
Vanguard Group, Inc
837489
Major Shareholders
Name Relationship
Total Shares
Holding stocks